Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet and exercise~* Body mass index (BMI) ≥ 25 kg/m\^2 and ≤ 40 kg/m\^2~* HbA1c 7 - 11%~* Ability and willingness to maintain a complete and accurate Subject Activity Log during the course of the trial~* Female of child-bearing potential must have agreed to use effective methods of contraception~* Ability to understand and willing to sign written informed consent~Exclusion Criteria:~* Type 1 Diabetes Mellitus (T1DM)~* T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable.~* History of ketoacidosis or ketosis-prone diabetes~* Clinically significant complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial~* History of a severe episode of hypoglycemia~* Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening~* Any clinically significant cardiovascular event \< 2 months prior to screening~* Clinically significant, inadequately controlled or unstable hypertension~* Hospitalization \< 2 months prior to screening~* Major surgery \< 3 months prior to screening~* Weight loss medication (prescription or non-prescription) \< 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: EXPERIMENTAL): Participants were randomized to receive ranolazine for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to receive placebo to match ranolazine for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).